This is a working overview of 合成七肽, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-15 and is reviewed periodically as new material appears.
常规纯度与身份确认依赖反相高效液相色谱，并辅以质谱测定分子量。氨基酸组成分析可用于验证序列构成，肽图分析则能进一步定位修饰或降解产物。杂质谱通常关注缺失序列肽、截短片段和氧化产物。不同方法的检出限并不相同，因此各实验室报告的纯度数值不宜直接横向比较。
多数实验室与市售的 Semax 以冻干粉形式提供。冻干粉通常建议保存在 -20 °C 或更低温度下，同时避免光照与反复升温。短期运输有时采用冷藏条件，但长期保存仍以冷冻为主。分包操作应尽量减少开盖次数，以降低吸湿和微生物污染的风险。开封后若未一次用完，建议在干燥环境中密封并尽快放回低温储存。
溶液状态的稳定性明显低于冻干粉。肽类在水溶液中可能经历水解、氧化与聚集，其中甲硫氨酸和天冬酰胺等残基常是敏感位点。Semax 含有甲硫氨酸，因此氧化风险相对突出。工作液一般主张现配现用，或冷藏并在数日内用尽。缓冲液种类、pH 和离子强度都会影响降解速率，而关于最佳条件的公开数据并不统一。
当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。
各国监管态度分化明显。俄罗斯按处方药管理，部分东欧国家留有使用记录；欧盟与美国未批准其作为药物上市，市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录，跨境携带则受目的地药品法规约束。
| Property | Value | Notes |
|---|---|---|
| 外观 | 白色至类白色粉末 | 常见于冻干制剂 |
| 溶解度 | 易溶于水 | 在极性溶剂中一般也可溶 |
| 建议储存温度 | -20 °C | 冻干粉，避光密封 |
| 常见分析手段 | 反相高效液相色谱 | 常与质谱联用 |
| 主要降解路径 | 水解与氧化 | 溶液状态更显著 |
Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.
Routine characterization relies on reversed-phase high-performance liquid chromatography to establish purity and on mass spectrometry to confirm molecular identity. Electrospray ionization and matrix-assisted laser desorption ionization are both used for mass verification. Amino acid analysis and peptide mapping can detect sequence errors. Common impurities include truncated sequences, methionine sulfoxide formed by oxidation, and deamidated products. Chromatograms are usually recorded near 214 nm, where the peptide backbone absorbs, and purity is reported as the percentage area of the principal peak.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
Flowers which are particularly suitable for such a treatment are roses, peonies, camellias, marigolds, globe flowers, orchids, dahlias, carnations, phloxes, summer chrysanthemums, hollyhocks, and the like, and other species with many petals or a fairly rigid structure.
The former maintains its own border control policies, thus requiring physical border security at its border with the Schengen Area, as well as implementing border controls for travellers travelling directly between Gibraltar and the British mainland. The latter maintains a relatively open border with Southern Cyprus, though not with Northern Cyprus. Consequently, it is a de facto member of the Schengen Area, and travel to or from the British mainland is subject to border controls. On 31 December 2020, Spain and the United Kingdom reached an agreement in principle under which Gibraltar would join the Schengen Area, clearing the way for the European Union and the UK to start formal negotiations on the matter. In the aftermath of Brexit, border controls for goods flowing between Great Britain and Northern Ireland were introduced in accordance with the Protocol on Ireland/Northern Ireland agreed to as part of the UK's withdrawal agreement with the EU. Due to the thirty-year internecine conflict in Northern Ireland, the UK-Ireland border has had a special status since that conflict was ended by the Belfast Agreement/Good Friday Agreement of 1998. As part of the Northern Ireland Peace Process, the border has been largely invisible, without any physical barrier or custom checks on its many crossing points; this arrangement was made possible by both countries' common membership of both the EU's Single Market and Customs Union and of their Common Travel Area.
p53 Also Tumor protein P53 (TP53), transformation-related protein 53 (TRP53), and cellular tumor antigen p53. A class of regulatory proteins encoded by the TP53 gene in vertebrates which bind DNA and regulate gene expression in order to protect the genome from mutation and block progression through the cell cycle if DNA damage does occur. It is mutated in more than 50% of human cancers, indicating it plays a crucial role in preventing cancer formation.
He progressed to the quarterfinals after winning over Jaume Munar of Spain, Tomáš Macháč of Czech Republic, and Alexei Popyrin of Australia, all in straight sets. He was defeated in the quarterfinals by eventual bronze medalist Lorenzo Musetti of Italy in straight sets. In the American hard court swing, Zverev reached the quarterfinals in Montréal, losing to Sebastian Korda in three sets. He went on to defend his semifinal points in Cincinnati, losing to Jannik Sinner in an attritive three-set match. At the US Open, he reached the quarterfinals without facing a seeded opponent, with wins over lucky loser Maximilian Marterer, wildcard Alexandre Müller, Tomás Martín Etcheverry and Brandon Nakashima — his 450th career win. With that milestone, he became the second player born in the 1990s, after Grigor Dimitrov, to reach 450 ATP wins. With the win, he qualified for his seventh appearance at the 2024 ATP Finals. Zverev lost in the quarterfinals to Taylor Fritz. At the Paris Masters, Zverev defeated Tallon Griekspoor, Arthur Fils, and Stefanos Tsitsipas to set up a semifinal clash with former champion Holger Rune. He won the match in straight sets to reach the final for the second time at this event. Zverev defeated home crowd favorite Ugo Humbert in the final to clinch his second Masters title of the season and the world No. 2 ranking. Zverev won all three of his group matches at the ATP Finals to reach the semifinals, where he lost to Taylor Fritz in a deciding set tie-break.
Sources: en.wikipedia.org
An erection is the stiffening and rising of the penis, which occurs during sexual arousal, though it can also happen in non-sexual situations. Spontaneous erections frequently occur during adolescence due to friction with clothing, a full bladder or large intestine, hormone fluctuations, nervousness, and undressing in a nonsexual situation. It is also normal for erections to occur during sleep and upon waking. (See nocturnal penile tumescence.) The primary physiological mechanism that brings about erection is the autonomic dilation of arteries supplying blood to the penis, which allows more blood to fill the three spongy erectile tissue chambers in the penis, the corpora cavernosa and corpus spongiosum, causing it to lengthen and stiffen. After vasocongestion, the now-engorged erectile tissue presses against and constricts the veins that carry blood away from the penis. More blood enters than leaves the penis until an equilibrium is reached where an equal volume of blood flows into the dilated arteries and out of the constricted veins; a constant erectile size is achieved at this equilibrium. Erection facilitates sexual intercourse though it is not essential for various other sexual activities.
===== State ===== Most states also have laws regulating pseudoephedrine. The states of Alabama, Arizona, Arkansas, California, Colorado, Delaware, Florida, Georgia, Hawaii (as of May 1, 2009) Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana (as of August 15, 2009), Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Jersey, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia and Wisconsin have laws requiring pharmacies to sell pseudoephedrine "behind the counter." Though the drug can be purchased without a prescription, states can limit the number of units sold and can collect personal information from purchasers. The states of Oregon and Mississippi previously required a prescription for the purchase of products containing pseudoephedrine. However, as of 1 January 2022, these restrictions have been repealed. The state of Oregon reduced the number of methamphetamine lab seizures from 448 in 2004 (the final full year before implementation of the prescription only law) to a new low of 13 in 2009. The decrease in meth lab incidents in Oregon occurred largely before the prescription-only law took effect, according to a NAMSDL report titled Pseudoephedrine Prescription Laws in Oregon and Mississippi.
Using Mendeleev's nomenclature for unnamed and undiscovered elements, oganesson is sometimes known as eka-radon (until the 1960s as eka-emanation, emanation being the old name for radon). In 1979, IUPAC assigned the systematic placeholder name ununoctium to the undiscovered element, with the corresponding symbol of Uuo, and recommended that it be used until after confirmed discovery of the element. Although widely used in the chemical community on all levels, from chemistry classrooms to advanced textbooks, the recommendations were mostly ignored among scientists in the field, who called it "element 118", with the symbol of E118, (118), or simply 118. Before the retraction in 2001, the researchers from Berkeley had intended to name the element ghiorsium (Gh), after Albert Ghiorso (a leading member of the research team). The Russian discoverers reported their synthesis in 2006. According to IUPAC recommendations, the discoverers of a new element have the right to suggest a name. In 2007, the head of the Russian institute stated the team were considering two names for the new element: flyorium, in honor of Georgy Flyorov, the founder of the research laboratory in Dubna; and moskovium, in recognition of the Moscow Oblast where Dubna is located. He also stated that although the element was discovered as an American collaboration, who provided the californium target, the element should rightly be named in honor of Russia since the Flyorov Laboratory of Nuclear Reactions at JINR was the only facility in the world which could achieve this result.
Sources: en.wikipedia.org
== Diversity == There are a large number of different odor receptors, with as many as 2,000 in the mammalian genome which, depending on the species represents up to 5% of the coding-genes in the genome. However, not all of these potential odor receptor genes are expressed and functional. According to an analysis of data derived from the Human Genome Project, humans have approximately 400 functional genes coding for olfactory receptors, and the remaining 600 candidates are pseudogenes. The reason for the large number of different odor receptors is to provide a system for discriminating between as many different odors as possible. Even so, each odor receptor does not detect a single odor. Rather each individual odor receptor is broadly tuned to be activated by a number of similar odorant structures. Analogous to the immune system, the diversity that exists within the olfactory receptor family allows molecules that have never been encountered before to be characterized. However, unlike the immune system, which generates diversity through in-situ recombination, every single olfactory receptor is translated from a specific gene; hence the large portion of the genome devoted to encoding OR genes. Furthermore, most odors activate more than one type of odor receptor. Since the number of combinations and permutations of olfactory receptors is very large, the olfactory receptor system is capable of detecting and distinguishing between a very large number of odorant molecules.
She is the youngest member of the main cast of the show and the only person of color in the main cast. She has discussed her grappling with the racial history of the Mormon church and her eventual leaving of the church. She has stated that she identifies as liberal. She has also discussed her struggles with eating disorders and her biracial identity, including hairstyle. She has stated she believes her biggest moment on the show in Season 3 was going to a Black hairstylist and changing her hairstyle. She has also criticized the show for how little airtime it gave her use of tirzepatide. She recounted her dating life, including with the brother of cast member Miranda Hope's ex-husband. She appeared on the runway for swimwear brand Oh Polly in 2026. On June 29, 2026, Taylor came out as bisexual on an episode of Jay Shetty's podcast, revealing that she had dated both men and women in the past. She also announced that she was in a relationship with a woman. After the revelation, most of her fellow cast members expressed support. A week later, she shared a video of her with the arm of her girlfriend in frame.
At the highest assessed dose in castrated male rats, levator ani weight was increased to around 140% of that of gonadally intact controls, whereas prostate weight was only increased to around 45% of that of intact controls. The tissue selectivity of LGD-4033 was independent of local tissue drug concentration, suggesting that its selectivity was intrinsic. The muscle-stimulating effects of LGD-4033 have also been confirmed in humans in preliminary clinical trials. The data also allow comparison between different SARMs and other AR agonists. In a phase 1 clinical trial in 76 healthy young men, 1 mg/day LGD-4033 increased lean body mass by 1.2 kg after 3 weeks of treatment. For comparison, enobosarm, another SARM, increased lean body mass by 1.3 kg at a dose of 3 mg/day after 12 weeks in healthy elderly men and postmenopausal women. It was concluded that the employed dose of LGD-4033 produced similar increases in lean body mass compared to enobosarm despite a substantially shorter treatment period. In a phase 2 clinical trial in 108 women and men with hip fracture, LGD-4033 increased lean body mass by 4.8% at 0.5 mg/day, 7.2% at 1 mg/day, and 9.1% at 2 mg/day after 12 weeks of treatment. For comparison, lean body mass with enobosarm 3 mg/day after the same time period of 12 weeks increased by about 0.30% at 0.1 mg/day, 0.40% at 0.3 mg/day, 1.2% at 1 mg/day, and 3.1% at 3 mg/day, with only the latter change achieving statistical significance.
In August 2004, Palatin signed an agreement with King Pharmaceuticals to co-develop bremelanotide in the US and jointly license it outside the US; King paid Palatin $20 million upfront. Palatin conducted Phase II trials of intranasal bremelanotide in both female sexual dysfunction (FSD) and male erectile dysfunction (ED), but these trials were halted by the FDA in 2007, due to increased blood pressure in clinical trial subjects; Palatin stopped development of the intranasal formulation in 2008. Four trials were conducted in ED, the last being a Phase IIb published in 2008. King terminated the co-development agreement shortly after the FDA halted the trials. The drug was then reformulated to be delivered by injection and trials continued in FSD. A phase II dose-finding trial in FSD in which the drug was administered 45 minutes before sex showed promise at the highest dose and only transient signs of high blood pressure; two Phase III trials were launched at the end of 2014. Palatin launched the Phase III trials with bremelanotide administered via an autoinjector. In 2014, Palatin licensed European rights to bremelanotide to Gedeon Richter Plc. for around $10 million, and Palatin received a milestone payment of around $3 million when it started the Phase III trials in the US. In September 2016, Palatin and Gedeon Richter terminated that agreement. In November 2016, Palatin announced results of the Phase III trials, and shortly thereafter began seeking a partner to complete development in the US.
Sources: en.wikipedia.org
一般不建议常温长期保存。多数说明指向 -20 °C 冷冻避光。常温运输通常被视为短期可接受，但会加快降解风险。
公开资料对此没有统一答案。普遍建议现配现用，或冷藏并在数日内用完。含甲硫氨酸的序列更易氧化，放置时间越长风险越高。
反相高效液相色谱是最常用的手段，配合质谱确认分子量。氨基酸组成分析和肽图分析可补充序列层面的验证。
不存在。它是依据 ACTH 的一段序列人工设计的分子，天然蛋白质中找不到与之完全相同的七肽。名称属于研究代号，而非天然物质名。